# Gene Kine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gene-kine

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.genekine.com.cn
- Latest round: Series A (Oct 16, 2018)
- Investors on record: 4

## About

Established in 2012 and based in Hangzhou, China, Gene Kine operates as a biotechnology developer that mainly engaged in the research, development and production of recombinant protein glycosylation. In October 2018, the company closed series A funding from new investors Platinum Hung Investment and ZCC Asset Management.

The company mainly engaged in the research, development and production of recombinant protein glycosylation. It develops Glycoengineered Pichia Pastoris expression system, IgG full-length antibody yeast display technology platform, and Bispecific Antibodies. Display technology is used for high-throughput screening of antibodies. Recombinant protein products and technical services involve many fields such as cell biology, immunity, neuroscience, tumors, stem cells, viruses, etc.

The company generates revenue by providing Glycoengineered Pichia Pastoris expression system, IgG full-length antibody yeast display technology platform, and Bispecific Antibodies.

## Funding rounds

- Series A, Oct 16, 2018 — ZCC Asset Management, PH Capital
- Angel, Jun 23, 2017 — United Fund, Zhejiang Pudu Technology

## Investors

- United Fund (https://capitalatlas.ai/funds/united-fund) — Angel
- Zhejiang Pudu Technology — Angel
- ZCC Asset Management (https://capitalatlas.ai/funds/zcc-asset-management) — Series A
- PH Capital — Series A